Modified FOLFOX6: Clinical Trials

6 trials of Modified FOLFOX6, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated, 1 withdrawn. 6 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Terminated 1, Withdrawn 1
Phase 11Completed 1
Phase 31Withdrawn 1

Follow Modified FOLFOX6: new trials by email Literature Review of Modified FOLFOX6 trials Research Report on Modified FOLFOX6

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NIS793, Bevacizumab, Modified FOLFOX6 - Metastatic Colorectal Cancer
Phase 2TerminatedNovartis Pharmaceuticals2042021-11-152025-03-26
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Bemarituzumab, Placebo, Modified FOLFOX6 - Gastric Cancer
Phase 2CompletedFive Prime Therapeutics, Inc.1552018-09-142024-02-28
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Modified FOLFOX6, Aflibercept, Surgery - Colorectal Cancer Metastatic, Liver Metastases
Phase 2 / Phase 3WithdrawnEuropean Organisation for Research and Treatment of Cancer - EORTC2012-12-012017-05-09
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Modified FOLFOX6, Conatumumab, Ganitumab - Advanced Solid Tumors, Carcinoid
Phase 2CompletedAmgen122011-03-032021-02-21
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Placebo, AMG 655, Modified FOLFOX6 - Metastatic Colorectal Cancer, Colon Cancer
Phase 1 / Phase 2CompletedAmgen2022007-10-012014-04-25
Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer
MODIFIED FOLFOX6 - Advanced Gastric Cancer
Phase 2CompletedSeoul National University Hospital522004-06-012025-04-17

Conditions studied

Colorectal Neoplasms (4)  ·  Carcinoid Tumor (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colonic Neoplasms (1)  ·  Lymphoma (1)  ·  Neoplasm Metastasis (1)  ·  Rectal Neoplasms (1)  ·  Sarcoma (1)  ·  Stomach Neoplasms (1)

Sponsors

Amgen (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Five Prime Therapeutics, Inc. (1)  ·  Novartis Pharmaceuticals (1)  ·  Seoul National University Hospital (1)

Countries

United States (4)  ·  South Korea (3)  ·  Spain (3)  ·  Australia (2)  ·  Belgium (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  Poland (2)  ·  Taiwan (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)

Top investigators

Bernard Nordlinger, Pr. (1)  ·  Seock-Ah Im, MD, PhD (1)

Results publications

PMID 32965540, PMID 36244398, PMID 38308771

NIH funding

2017 (1)